Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Unternehmen & Branche
| Name | Terns Pharmaceuticals, Inc. |
|---|---|
| Ticker | TERN |
| CIK | 0001831363 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 4,77 Mrd. USD |
| Beta | -0,38 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -96,207,000 | -1.03 | 1,025,078,000 | 1,006,524,000 | |
| 2025-09-30 | 10-Q | -24,635,000 | -0.27 | 301,651,000 | 284,066,000 | |
| 2025-06-30 | 10-Q | -24,093,000 | -0.26 | 320,415,000 | 305,229,000 | |
| 2025-03-31 | 10-Q | -23,908,000 | -0.26 | 339,315,000 | 326,043,000 | |
| 2024-12-31 | 10-K | -88,853,000 | -1.12 | 363,929,000 | 345,870,000 | |
| 2024-09-30 | 10-Q | -21,945,000 | -0.28 | 378,233,000 | 364,470,000 | |
| 2024-06-30 | 10-Q | -22,736,000 | -0.31 | 230,880,000 | 218,681,000 | |
| 2024-03-31 | 10-Q | -22,373,000 | -0.30 | 246,766,000 | 236,720,000 | |
| 2023-12-31 | 10-K | -90,210,000 | -1.27 | 268,517,000 | 255,367,000 | |
| 2023-09-30 | 10-Q | -29,767,000 | -0.42 | 271,687,000 | 258,425,000 | |
| 2023-06-30 | 10-Q | -17,896,000 | -0.25 | 289,697,000 | 274,150,000 | |
| 2023-03-31 | 10-Q | -21,528,000 | -0.31 | 301,285,000 | 287,683,000 | |
| 2022-12-31 | 10-K | 0 | -60,345,000 | -1.67 | 287,026,000 | 276,943,000 |
| 2022-09-30 | 10-Q | -16,820,000 | -0.44 | 192,586,000 | 183,694,000 | |
| 2022-06-30 | 10-Q | -13,930,000 | -0.55 | 144,860,000 | 137,216,000 | |
| 2022-03-31 | 10-Q | -13,773,000 | -0.55 | 156,669,000 | 148,716,000 | |
| 2021-12-31 | 10-K | 1,000,000 | -50,158,000 | -2.21 | 168,070,000 | 160,303,000 |
| 2021-09-30 | 10-Q | -11,835,000 | -0.47 | 179,890,000 | 172,156,000 | |
| 2021-06-30 | 10-Q | -10,738,000 | 188,007,000 | 181,332,000 | ||
| 2021-03-31 | 10-Q | -13,337,000 | 199,241,000 | 190,002,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Kuriakose Emil | Officer, Chief Medical Officer | Open Market Sale | -942 | 52.75 | -49,692.95 | -13,0% | |
| 2026-02-17 | Burroughs Amy L. | Director, Officer, Chief Executive Officer | Open Market Sale | -8,159 | 39.22 | -319,963.34 | -83,9% | |
| 2026-02-17 | Burroughs Amy L. | Director, Officer, Chief Executive Officer | Open Market Sale | -4,083 | 39.80 | -162,501.36 | -42,6% | |
| 2026-02-17 | Burroughs Amy L. | Director, Officer, Chief Executive Officer | Open Market Sale | -2,341 | 38.07 | -89,114.38 | -23,4% | |
| 2026-01-15 | Burroughs Amy L. | Director, Officer, Chief Executive Officer | Open Market Sale | -7,521 | 37.53 | -282,230.04 | -74,0% | |
| 2026-01-15 | Burroughs Amy L. | Director, Officer, Chief Executive Officer | Open Market Sale | -61,228 | 37.02 | -2,266,372.79 | -594,4% | |
| 2026-01-05 | Burroughs Amy L. | Director, Officer, Chief Executive Officer | Open Market Sale | -71,339 | 38.10 | -2,718,229.92 | -713,0% | |
| 2026-01-02 | Kuriakose Emil | Officer, Chief Medical Officer | Open Market Sale | -200 | 39.60 | -7,920.00 | -2,1% | |
| 2026-01-02 | Kuriakose Emil | Officer, Chief Medical Officer | Open Market Sale | -955 | 38.36 | -36,632.46 | -9,6% | |
| 2025-11-04 | Quigley Jill M. | Director | Open Market Sale | -24,520 | 18.00 | -441,360.00 | -115,8% | |
| 2025-10-01 | Kuriakose Emil | Officer, Chief Medical Officer | Open Market Sale | -944 | 7.85 | -7,407.00 | -1,9% | |
| 2025-07-01 | Kuriakose Emil | Officer, Chief Medical Officer | Open Market Sale | -853 | 4.27 | -3,639.84 | -1,0% | |
| 2025-06-27 | Gengos Andrew | Officer, Chief Financial Officer | Open Market Purchase | 5,000 | 3.93 | 19,649.50 | +5,2% | |
| 2025-06-27 | Gengos Andrew | Officer, Chief Financial Officer | Open Market Purchase | 5,000 | 3.93 | 19,633.50 | +5,1% | |
| 2025-06-16 | Gengos Andrew | Officer, Chief Financial Officer | Open Market Purchase | 5,000 | 3.95 | 19,732.50 | +5,2% | |
| 2025-06-13 | Gengos Andrew | Officer, Chief Financial Officer | Open Market Purchase | 5,000 | 3.72 | 18,600.00 | +4,9% | |
| 2025-06-13 | Gengos Andrew | Officer, Chief Financial Officer | Open Market Purchase | 5,000 | 3.75 | 18,750.00 | +4,9% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.